Published in Proc Natl Acad Sci U S A on July 23, 2008
The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol (2011) 2.69
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther (2015) 1.73
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol (2013) 1.33
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. Structure (2015) 1.27
The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J Immunol (2014) 1.01
Phenotype and regulation of immunosuppressive Vδ2-expressing γδ T cells. Cell Mol Life Sci (2013) 0.90
HIV-1 Tat protein induces PD-L1 (B7-H1) expression on dendritic cells through tumor necrosis factor alpha- and toll-like receptor 4-mediated mechanisms. J Virol (2014) 0.85
The effects of PDL-Ig on collagen-induced arthritis. Rheumatol Int (2009) 0.82
Costimulatory genes: hotspots of conflict between host defense and autoimmunity. Immunity (2013) 0.76
Costimulation Blockade in Kidney Transplantation: An Update. Transplantation (2016) 0.75
Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer. J Immunother Cancer (2017) 0.75
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity (2007) 8.94
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res (2006) 8.21
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol (2004) 7.16
PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol (2007) 6.24
Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol (2003) 6.07
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol (2004) 4.58
B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med (Berl) (2003) 2.48
Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature (2001) 2.42
Structure and dimerization of a soluble form of B7-1. Immunity (2000) 2.33
Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature (2001) 2.21
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc Natl Acad Sci U S A (2008) 2.03
Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc Natl Acad Sci U S A (2008) 1.55
Structural basis of CD8 coreceptor function revealed by crystallographic analysis of a murine CD8alphaalpha ectodomain fragment in complex with H-2Kb. Immunity (1998) 1.51
Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proc Natl Acad Sci U S A (2007) 1.28
Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med (2006) 4.17